NCT05031624View on ClinicalTrials.gov

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Healthy Subjects
Interventions
DRUG

CDX-0159

Single subcutaneous dose of one of four dosages of CDX-0159

DRUG

Normal saline

Single subcutaneous dose of normal saline

Trial Locations (1)

68502

Celerion, Inc, Lincoln

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT05031624 - A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | Biotech Hunter | Biotech Hunter